Norethisterone oenanthate (NET-OEN) was given as an injectable contraceptive to 295 healthy women over 1606 woman-months. A modified injection schedule was used. There were no pregnancies, and the 12-month, life-table, use-related discontinuation rate was 39 1/100 users. Menstrual disturbance (10 8/100 women), minor side effects (13 5/100 women), and personal reasons (12 0/100 women) were the main causes of use-related discontinuation. There was no difference in use-related discontinuation rates between women receiving their first injection during a normal menstrual period and those receiving it immediately after a pregnancy. There were no serious side effects.
Introduction
The discovery by Junkman that the esterification of a progestogen alcohol produced a systematically active long-acting progesten led to the synthesis of a series of long-acting fertility-regulating agents.' During the past 15 and that only for short-term use.7 DMPA is effective in preventing pregnancy, with quoted failure rates of 0-12/100 woman-years and over 77 000 woman-years of experience reported worldwide. It may not be the drug of choice for longterm use owing to a high incidence of amenorriloea and irregular bleeding patterns. In a multinational study8 comparing DMPA with NET-OEN given at 12-weekly intervals, patients using NET-OEN were found to have less amenorrhoea but significantly more pregnancies.
NET-OEN has been the subject of clinical trials in England for the past two and a half years. We report our experience with the drug given on a modified injection schedule.
Patients and methods
Patients were recruited from the family planning clinics, gynaecology wards, and postnatal wards of King's College Hospital. Informed consent was obtained from all. Only healthy women aged 18-45 years were admitted to the study. Unless they had recently delivered or been pregnant they were required to have a history of regular menstrual cycles, with a variation of not more than 10 days between the longest and the shortest menstrual cycles in the last three months. Patients who normally used hormonal contraceptives stopped using them for at least four weeks before the study.
Injection schedule-NET-OEN was supplied in ampoules containing 200 mg of the steroid in 1 ml of an oily solution. The ampoule was warmed in hot tap water and the drug given as an intramuscular injection into the gluteal muscles. A modified injection schedule was used. The first injection was given during days 1-5 of a normal menstrual period or before discharge from hospital after confinement or termination of pregnancy. The second, third, and fourth injections were given at eight-week intervals. Subsequent injections were given at 12-week intervals. (table II) . There was no significant difference in age (P 0 025) or parity (P, 0-10) between the two groups. The overall use-related discontinuation rates were 39-1/100 women at 12 months and 49-2/100 women at 18 months.
Thirty patients failed to attend for injection within seven days of the scheduled date and were recorded as lost to follow-up. The x2 test comparison of those who started treatment during a menstrual period (204 patients) with those who began after a pregnancy (91 patients) showed no difference in the probability of discontinuing treatment (P 0--O 1 0). 
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Discussion
Injectable contraceptives have several advantages: they are simple to administer, require minimum patient compliance with the administration schedule and so reduce the user's error, are independent of coitus, cannot be detected, do not interfere with lactation,"' and are highly effective. Experience with DMPA in several countries confirmed these advantages; there were low pregnancy rates and typical 12-month continuation rates of 49-80/100 woman-years.5 1213 Wilson'4 found DMPA useful in high-risk patients in Glasgow. Experience with NET-OEN is more limited, and there are no other reports of its use for contraception in the United Kingdom. Although El-Mahgoub and Karim6 found no pregnancies in women given NET-OEN every 90 days, reported pregnancy rates for NET-OEN given every 84-90 days have tended to be higher than those for DMPA. Kesseru-Koos et al'5 reported a pregnancy rate of 149/100 woman-years among 1844 women given NET-OEN every 12 weeks, while in a recent multinational study in which NET-OEN or DMPA was given every 12 weeks, a 12-month gross pregnancy rate of 3 6/100 woman-years was found for NET-OEN compared with 0-6/100 woman-years for DMPA.8 Seventy-five per cent of the pregnancies with NET-OEN occurred in the first injection interval, mostly in the last four weeks.
Studies of the return of ovulation in patients given a single injection of NET-OEN showed that ovulation may be restored in most cases by day 80.16 1' In one study17 two out of eight patients ovulated by day 55 and another three ovulated between days 55 and 80. By using a modified injection schedule no pregnancies occurred in our series. Hormone profiles18 showed that when using this modified injection schedule ovulation does not occur. This consistent suppression of ovulation and the recognised effects of NET-OEN on cervical mucus probably account for the improved contraceptive efficacy of NET-OEN when given on a modified injection schedule. Giving the first injection during a menstrual period or before discharge from hospital after confinement or termination of pregnancy ensures that no patient is injected in the presence of an early unrecognised pregnancy.
Unpredictable vaginal bleeding is a major disadvantage of injectable progestogen contraception. A recent study8 19 showed that the discontinuation rates for bleeding irregularities were similar for NET-OEN and DMPA but that the incidence of amenorrhoea was at least three times higher in DMPA users, and that there were more discontinuations for amenorrhoea in DMPA users (11-5/100 women) than in NET-OEN users (18/100 women). In our study, using a NET-OEN injection schedule which is more likely to produce anovulation and amenorrhoea, the 12-month discontinuation rate for amenorrhoea was 1-4/100 women, which is similar to the rate reported in the multinational study.8 We also found that menstrual irregularity was more common in the first two injection intervals and that discontinuations were more likely to occur in the first four months of treatment. Other investigators'5 have reported regular cycles in 58 6%/ of patients and amenorrhoea in 23 6%' during the first year of treatment. They also reported that regular cycles increased while the incidence of amenorrhoea decreased in patients who continued for three years. Although we cannot confirm these findings, as the duration of our study was comparatively short, if patients are more likely to discontinue because of menstrual abnormality early in treatment, probably the proportion of those discontinuing because of amenorrhoea later on will decrease.
Howard et aP21' found that NET-OEN did not adversely affect blood clotting factors or glucose tolerance, while in the multinational study8 no change was detected in blood pressure. Few patients on NET-OEN have an appreciable increase in weight. These added advantages permit the use of NET-OEN in some patients in whom oral contraceptives are contraindicated. In our study two patients were withdrawn because of raised blood pressure, while 10 discontinued because of weight gain.
Unlike Wilson,14 who used DMPA in patients at high risk of pregnancy in Glasgow, we studied NET-OEN as part of a comprehensive family-planning programme. We have found NET-OEN to be highly effective and to have few serious side effects. The continuation rate is similar to that for oral contraceptives and less than that for an intrauterine device. 21 In addition to short-term contraceptive use, for which DMPA has been approved by the Committee on Safety of Medicines, we feel that NET-OEN may be used for any woman who desires or needs highly effective contraception, particularly if she does not mind having menstrual irregularity; women who do not wish to use oral contraceptives or for whom they are contraindicated because of the risk of thromboembolism or cardiovascular disease; lactating women; and any woman awaiting hospital admission for sterilisation.
Introduction
Appendicitis is one of the most common acute surgical conditions in the UK, particularly among young people. Emergency admission to hospital and emergency appendicectomy are the common sequelae. A study of all hospital admissions for appendicitis in Wales in 1971 identified 5018 first admissions, which is equivalent to a yearly first-admission rate of about 1 9/1000 population.' There are wide variations, however, both between countries2-for example, the yearly admission rate in West Germany in 1966 was about 5-7/10003 -and between hospital regions in England-21/1000 yearly in the South-east London region and 14/1000 in Sheffield in 1972. 4 We report briefly a study of the rates of admission to hospital for appendicitis in Wales in 1976, in which we examined the rates for each of the 17 health districts by age and sex of the patients and by the season and day of the week of admission, and in which we calculated the mean length of stay in the major hospitals serving the districts.
